Clinical Microbiology: Open Access

Badiee and Hashemizadeh, Clin Microbiol 2016, 5:3
DOI: 10.4172/2327-5073.1000250

Short Communication Open Access

# Why is Therapeutic Drug Monitoring for Voriconazole Essential in the Treatment of Fungal Infections

**Parisa Badiee and Zahra Hashemizadeh***

*Prof. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran*

***Corresponding author:** Hashemizadeh Zahra, Department of Clinical Microbiology, Prof. Alborz Research Centre, Namazee Hospital Zand Ave., Shiraz, Iran, Tel: 98 71-3647-4292; Fax: 98 71-3647-4303; **E-mail:** zh.hashemiz@gmail.com

**Received date:** May 18, 2016; **Accepted date:** June 16, 2016; **Published date:** June 26, 2016



## Introduction

Fungal infections are frequent life-threatening complications in immune compromised patient sand in patients admitted in ICU wards [1]. Voriconazole (VRC) is a second-generation wide-spectrum anti-fungal triazole recommended for the treatment of potentially life-threatening fungal infections including invasive *aspergillosis,* disseminated *candidasies,* and other infections caused by *Fusarium* and *Scedosporium* spp. [2,3]. This compound can be administered as an intravenous infusion and oral formulations. Studies with healthy volunteers demonstrated bioavailability of >90% after oral administration [4]. A steady-state level is achieved in three days with two loading doses of 400 mg for the first day, followed by a maintenance dose of 200 mg every 12 hours thereafter [5]. Investigations have shown both within and between individual's variability in VRC steady-state plasma concentration and non-linear pharmacokinetics due to saturation of its metabolism with respect to dose. This variability was observed with both intravenous and oral formulations [6]. Other pharmacokinetic variability's include decreased absorption of oral VRC with meals, interactions with co-medications, patient's age, hepatic inefficiency and genetic polymorphisms of cytochrome P450 (CYP) iso-enzymes, mainly CYP2C19 enzyme [6,7]. Generally accepted plasma level for VRC is 1-5.5 mg/L. There have been reports that a clear relationship exists between drug concentration and drug response. High levels (>5.5 mg/L) are associated with variant adverse drug reactions. The most frequently side effects of VRC are vomiting , nausea , fever, skin rash, vision color changes, visual disturbances, blurred vision, hepatotoxicity, liver enzyme elevation, encephalopathy, and electrolyte abnormalities. Levels of VRC (<1 mg/L) have been associated with therapeutic failures and breakthrough infection [8]. In addition, using recommended dosing regimens in both adults and pediatrics has shown a significant relationship between VRC plasma levels and clinical efficacy and/or toxicity indicating a need for therapeutic drug monitoring (TDM). TDM may enable clinicians to make a better use of VRC, and is recommended as a tool to individualize VRC doses and may be particularly helpful in the context of preventing drug-related side effects. Therefore, TDM of VRC concentrations is highly recommended to maximize efficacy and minimize adverse events [9].

To perform therapeutic drug monitoring, several available analytic methods enabled quantified the VRC concentration in human plasma or serum. Most of these assays use high-performance liquid chromatography methods with ultra-violet detection (HPLC-UV) or coupled with mass spectrophotometry. Other methods such as bioassays or microbiological assays have also been investigated as a valid alternative to chromatographic methods. Bioassays can determine the total antifungal activity of a drug, conversely, HPLC or ultra-HPLC quantify the concentrations of VRC but cannot assess its activity [10].

In conclusion, *Candida* and *Aspergillus* spp. are the most common causes of invasive fungal infections with high morbidity and mortality in immune compromised patients [1,11,12]. Voriconazole, compared with other antifungal agents, has potent activity against a broader spectrum of clinically significant fungal pathogens, including *Aspergillus, Candida* spp., especially *Candida krusei* and *Candida glabrata* which resist other antifungal agents [13]. Using VRC in combination with TDM can serve as the best method for the survival of patients.

## Acknowledgement

The authors would like to thank Dr. Hassan Khajea PhD, for copy editing of the manuscript.

## References

1. Badiee P, Alborzi A, Joukar M (2011) Molecular assay to detect nosocomial fungal infections in intensive care units. Euro J Intern Med. 22: 611-615.
2. Herbrecht R (2004) Voriconazole: therapeutic review of a new azole antifungal.Expert Rev Anti Infect Ther 4: 485-497.
3. Badiee P, Alborzi A, Moeini M, Haddadi P, Farshad S, et al.(2012) Antifungal susceptibility of the Aspergillusspecies by e-test and CLSI reference methods. Arch Iran Med 7: 429-32.
4. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD (2003) Voriconazole, anovel wide-spectrum triazole: oral pharmacokinetics andsafety. Br J ClinPharmacol 56: 10-16.
5. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, et al. (2003)The pharmacokinetics and safety of intravenous voriconazole a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 56: 2-9.
6. Pasqualotto AC, Shah M, Wynn R, Denning DW (2008) Voriconazole plasmamonitoring. Arch Dis Child 93: 578-581.
7. Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, et al. (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 802: 126-135.
8. Lewis RE (2011) Current Concepts in Antifungal Pharmacology. Mayo Clin Proc 86: 805-817.
9. Brüggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A (2011) Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 30: 533-534.
10. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, et al. (2010) Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B AnalytTechnol Biomed Life Sci 878: 39-44.
11. Badiee P, Alborzi A (2010) Detection of Aspergillus species in bone marrow transplant patients. J Infect DevCtries 4: 511-516.

12. Badiee P, Alborzi A, Malekhosseini SA, Nikeghbalian S, Shakiba E (2010) Determining the incidence of aspergillosis after liver transplant. ExpClin Transplant 3: 220-223.

13. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, et al. (2016) Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Practice Guideline for the Management of Candidiasis CID: 62.